Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928041 · ClinicalTrials.gov registry record · NA
A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine
A NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1, sponsored by Invibio.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT03928041: Completed NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1, sponsored by Invibio.
NCT03928041 is a NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1 that has completed, run by Invibio. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03928041, a NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1, has completed, sponsored by Invibio.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo interbody spinal fusion using the EVOS Lumbar Interbody System.
Primary Outcome
Interbody fusion will be graded in accordance with Cook et al. 2004 where bridging bone is graded along the superior and inferior interfaces separately in 25% increments.
Conditions Studied
Interventions
- DEVICE Device: EVOS Lumbar Interbody System (EVOS-HA)
Study Locations (2)
North Carolina
- OrthoCarolina Research Institute - Charlotte
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2023-09-25 |
| Phase | NA |
What the finished NCT03928041 record still lists
NCT03928041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Degenerative Disc Disease Lumbar appearing as the primary indexed condition, and to 1 intervention - of which Device: EVOS Lumbar Interbody System (EVOS-HA) is the first listed.
NCT03928041 reports a single indexed study location in North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03928041 about?
NCT03928041 is a clinical study titled "A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine". The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo interbody spinal fusion using the EVOS Lumbar Interbody System.
What is the current status of trial NCT03928041?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2019-06-27. Estimated completion is 2023-09-25.
What conditions does trial NCT03928041 study?
This clinical trial studies the following conditions: Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1.
What interventions are being tested in trial NCT03928041?
The interventions under investigation include: Device: EVOS Lumbar Interbody System (EVOS-HA) (DEVICE).
Who is sponsoring clinical trial NCT03928041?
This trial is sponsored by Invibio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03928041 being conducted?
This trial has 2 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Disc Disease Lumbar
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03928041's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI